Head-to-head evidence
Ametinib vs BPI-361175
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Ametinib
Developed by Hansoh Pharmaceutical Group and partners
NCT05754736 · Phase 2 · status unknown
This is a single-arm, open-label study with no comparator group, so there is no way to know whether the combination performs better than existing treatments. Results on tumor response and progression-free survival have not yet been posted.
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ametinib's landscape · BPI-361175's landscape